| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/498119 |
| P698 | PubMed publication ID | 16288392 |
| P50 | author | Jordi Rello | Q37370747 |
| Jordi Almirall | Q40592307 | ||
| Maria Bodí | Q70678722 | ||
| Alejandro Rodriguez | Q79150378 | ||
| P2093 | author name string | N Carrasco | |
| F García | |||
| J M Sirvent | |||
| J Solé-Violán | |||
| J Vallés | |||
| J Jimenez | |||
| J Blanquer | |||
| R Jordá | |||
| J Garnacho | |||
| A Mendia | |||
| M J Broch | |||
| F Bobillo | |||
| A Doblas | |||
| Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators | |||
| J R Badía | |||
| M A Herranz | |||
| M C Gilavert | |||
| M V de la Torre | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| pneumonia | Q12192 | ||
| intensive care unit | Q5094647 | ||
| P304 | page(s) | 1709-1716 | |
| P577 | publication date | 2005-11-09 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival | |
| P478 | volume | 41 |
| Q44498045 | A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. |
| Q57237937 | Advances in lower respiratory tract infections in critically ill patients |
| Q37702741 | Burden of community-acquired pneumonia in North American adults |
| Q34999131 | Choosing the right combination therapy in severe community-acquired pneumonia |
| Q41089114 | Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes |
| Q57237831 | Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia |
| Q59135084 | Community acquired pneumonia among adult patients at an Egyptian university hospital: bacterial etiology, susceptibility profile and evaluation of the response to initial empiric antibiotic therapy |
| Q34048462 | Community-acquired pneumonia in elderly patients |
| Q43974180 | Community-acquired pneumonia versus healthcare-associated pneumonia. The returning pendulum |
| Q27002420 | Community-acquired pneumonia: identification and evaluation of nonresponders |
| Q38842229 | Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy |
| Q38105639 | Current treatment of community-acquired pneumonia |
| Q21195015 | Demographics, guidelines, and clinical experience in severe community-acquired pneumonia |
| Q33589527 | Disparities of care for African-Americans and Caucasians with community-acquired pneumonia: a retrospective cohort study |
| Q92069062 | Economic Burden Of Inappropriate Empiric Antibiotic Therapy: A Report From Southern Iran |
| Q60046341 | Effectiveness of influenza and pneumococcal polysaccharide vaccines against influenza-related outcomes including pneumonia and acute exacerbation of cardiopulmonary diseases: Analysis by dominant viral subtype and vaccine matching |
| Q91128701 | Effectiveness of repeated influenza vaccination among the elderly population with high annual vaccine uptake rates during the three consecutive A/H3N2 epidemics |
| Q37896600 | Elderly patients with community-acquired pneumonia: optimal treatment strategies |
| Q38058280 | Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. |
| Q30452249 | Fluoroquinolones in the management of community-acquired pneumonia in primary care |
| Q84013366 | Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid Services |
| Q49082117 | Healthcare-associated pneumonia: another nail in the coffin? |
| Q33890474 | Hospital-reported data on the pneumonia quality measure "Time to First Antibiotic Dose" are not associated with inpatient mortality: results of a nationwide cross-sectional analysis |
| Q35137726 | Impact of preceding flu-like illness on the serotype distribution of pneumococcal pneumonia. |
| Q39364894 | Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter case-control study |
| Q36061715 | Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study |
| Q54245877 | Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis. |
| Q37747381 | Levofloxacin in the treatment of community-acquired pneumonia. |
| Q40863201 | Management of community-acquired pneumonia in an Australian regional hospital. |
| Q43596478 | Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. |
| Q36855541 | Neutropenic Sepsis in the ICU: Outcome Predictors in a Two-Phase Model and Microbiology Findings |
| Q35999180 | Non-adherence to antimicrobial treatment guidelines results in more broad-spectrum but not more appropriate therapy |
| Q37362652 | Novel targets in the management of pneumonia |
| Q36514914 | Optimal therapy for severe pneumococcal community-acquired pneumonia |
| Q33752549 | Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort |
| Q35021125 | Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization |
| Q64131294 | Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico |
| Q38202574 | Respiratory infections |
| Q37084772 | Risk factors for mortality in patients admitted to intensive care units with pneumonia |
| Q87052081 | Severe community-acquired pneumonia |
| Q43812056 | Severe community-acquired pneumonia and PIRO: a new paradigm of management |
| Q37557686 | Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy |
| Q90751446 | Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection |
| Q47647459 | Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients |
| Q38181699 | Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia |
| Q57237914 | Severity of illness assessment for managing community-acquired pneumonia |
| Q37781944 | Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis |
| Q27028133 | The effect of diabetes on mortality in critically ill patients: a systematic review and meta-analysis |
| Q42134928 | The prognostic value of muscle regional oxygen saturation index in severe community-acquired pneumonia: a prospective observational study. |
| Q35802896 | The use of three strategies to improve quality of care at a national level |
| Q37867267 | Treatment algorithms in critical care: do they improve outcomes? |
| Q57806122 | Variation in Emergency Department Adherence to Treatment Guidelines for Inpatient Pneumonia and Sepsis: A Retrospective Cohort Study |
| Q84134495 | [Bacterial infections in critically ill patients: review of studies published between 2006 and 2008] |
| Q82707771 | [Infectious comorbidity in COPD] |
| Q80156119 | [Pseudomonas aeruginosa: combined treatment vs. monotherapy] |
| Q80152108 | [Treatment of community acquired pneumonia] |
| Q91910734 | [Which samples to obtain in the emergency department for the microbiological diagnosis of community-acquired pneumonia in the immunocompetent patient?] |
Search more.